HeartBeam to Showcase FDA-Cleared Cardiac Technology at JP Morgan Healthcare Conference

HeartBeam Inc. (NASDAQ: BEAT) announced its participation in the JP Morgan 2026 Annual Healthcare Conference, where company executives will meet with investors and potential partners to discuss recently obtained regulatory clearances and planned commercialization of its innovative cardiac monitoring technology. The conference will take place from January 12 to 15, 2026, at the Westin St. Francis Hotel in San Francisco, with CEO Robert Eno and CFO Timothy Cruickshank available for meetings from January 12 through 14.

The company's attendance at this prominent healthcare investment conference comes at a critical juncture following U.S. Food and Drug Administration clearance for its patented cable-free 12-lead electrocardiogram synthesis software. This regulatory milestone, achieved through the 510(k) clearance pathway, enables the medical technology company to proceed with a limited commercial launch planned for the first quarter of 2026. The technology represents a significant advancement in cardiac care by allowing portable collection of electrocardiogram signals from three non-coplanar directions, which are then synthesized into a 12-lead ECG format traditionally only available in clinical settings.

HeartBeam's platform technology addresses a fundamental limitation in current cardiac monitoring by enabling comprehensive ECG assessment outside medical facilities. According to company information available at https://HeartBeam.com, the system creates the first cable-free device capable of collecting ECG signals in three dimensions and synthesizing them into a 12-lead ECG. This innovation could potentially transform how physicians monitor cardiac conditions, allowing them to identify health trends and acute conditions while patients remain in their homes or other non-clinical environments.

The FDA clearance specifically covers assessment of normal sinus rhythm and several non-life-threatening arrhythmias including sinus arrhythmia, sinus tachycardia, sinus bradycardia, atrial premature complexes, atrial fibrillation, and ventricular premature complex. The regulatory clearance documentation emphasizes that the synthesized 12-lead ECG output is not intended for assessment of life-threatening conditions including myocardial infarction, ischemia, ventricular arrhythmias, or pacemaker functions, and does not replace standard 12-lead ECGs for comprehensive cardiac evaluation.

With over 20 issued patents supporting its technology, HeartBeam's approach to cardiac monitoring represents a shift toward decentralized healthcare delivery. The ability to obtain clinically relevant cardiac data outside traditional medical settings could significantly impact patient access to monitoring, particularly for those with mobility limitations, in rural areas, or requiring frequent assessment. The company's presence at the JP Morgan conference signals its readiness to engage with commercialization partners and investors who recognize the growing market for remote patient monitoring technologies.

The broader implications of this technology extend beyond immediate clinical applications to potentially reduce healthcare system burdens by enabling earlier intervention and reducing unnecessary hospital visits. As the company prepares for its commercial launch, the investment community's response during the conference may influence the pace of adoption for this novel approach to cardiac care. Additional information about the company is available through its newsroom at https://nnw.fm/BEAT, though the technology's ultimate impact will depend on successful implementation and physician adoption in clinical practice.